Skip to main content
. Author manuscript; available in PMC: 2023 Feb 10.
Published in final edited form as: J Am Med Dir Assoc. 2022 Mar 23;23(11):1854–1860. doi: 10.1016/j.jamda.2022.02.010

Table 3.

Cox Models for Months to Death

Model 0 Model 1 Model 2 Model 3*
N 6523 6791 6523 2758
n (%) Censored 1447 (22.2%) 1496 (22.0%) 1447 (22.2%) 705 (25.6%)
Variable HR (95% CI)** HR (95% CI) HR (95% CI) HR (95% CI)
Treatment Decision (vs. Treatment/No Hospice [Group 3]):
 No Treatment/No Hospice [Group 1] 1.08 (1.002–1.17) 1.61 (1.48–1.75) 1.40 (1.23–1.58)
 Treatment/Hospice [Group 4] 2.98 (2.68–3.31) 2.09 (1.88–2.33) 1.99 (1.69–2.35)
 No Treatment/Hospice [Group 2] 3.40 (3.13–3.69) 2.90 (2.66–3.18) 2.84 (2.48–3.25)
Total ADL score:
 First Assessment 1.04 (1.03–1.05)
 Improvement 0.93 (0.92–0.95)
Male (vs. Female) 1.16 (1.10–1.23) 1.17 (1.11–1.24) 1.20 (1.10–1.32)
Age at Index Admission (10 years) 1.19 (1.14–1.23) 1.06 (1.02–1.11)
Months between Diagnosis and Index Admission 0.93 (0.90–0.96) 0.93 (0.91–0.96) 0.94 (0.90–0.98)
SES
Median Income ($10,000) 0.98 (0.97–0.99) 0.98 (0.97–0.99)
Charlson Comorbidity Index Categories 1.07 (1.05–1.10) 1.05 (1.03–1.08)
Cancer Type (vs. Colorectal)
 Lung 1.87 (1.72–2.03) 1.88 (1.73–2.04) 2.06 (1.81–2.35)
 Pancreas 2.29 (2.05–2.57) 2.20 (1.96–2.46) 2.36 (1.97–2.84)
 Bladder 1.89 (1.64–2.18) 1.80 (1.56–2.07) 1.86 (1.51–2.30)
Cancer Stage (vs. Stage IV)
 Stage II 0.34 (0.31–0.37) 0.35 (0.32–0.38) 0.38 (0.33–0.43)
 Stage III 0.52 (0.48–0.56) 0.56 (0.52–0.60) 0.58 (0.52–0.66)
Grade (vs. 9)
 1 0.43 (0.36–0.52) 0.48 (0.40–0.58) 0.48 (0.36–0.64)
 2 0.61 (0.56–0.67) 0.66 (0.60–0.73) 0.70 (0.61–0.82)
 3 0.87 (0.80–0.94) 0.93 (0.86–1.005) 0.97 (0.86–1.10)
 4 0.90 (0.78–1.03) 0.98 (0.85–1.12) 1.16 (0.94–1.43)
Index LOS (10 days) 1.07 (1.03–1.10) 1.09 (1.05–1.13)
*

Many cases were not used in the model since improvement in total ADL score was available for only 2758 patients.

**

Hazard Ratio (95% Confidence Interval)